Trends in First Tier Biotech In-Licensing
Executive SummaryIn terms of total in-licensing dollar volume, first-tier biotechs (defined as biotechs with a cap over $1 billion) aren't in the same league as Big Pharma (the top 20 pharmaceutical companies ranked by worldwide sales)--but that's slowly and steadily changing.
You may also be interested in...
The US Court of Appeals for the Federal Circuit has upheld a series of inter partes review decisions from 2017 in which three Humira patents were found invalid by the Patent Trial and Appeal Board within the US Patent and Trademark Office.
An ambitious action plan drawn by an EU task force, if implemented on a priority basis by the European Commission, could increase the EU’s capacity to advise on, assess and analyze big data.